VALUE OF AMINOPYRINE
Authors: L CARDON, O H COMESS, T A NOBLE, M M POMARANC
Journal: Annals of Internal Medicine (1958)

Article1 March 1958VALUE OF AMINOPYRINELEONARD CARDON, M.D., F.A.C.P., OSCAR H. COMESS, M.D., THOMAS A. NOBLE, M.D., MARK M. POMARANC, M.D.LEONARD CARDON, M.D., F.A.C.P.Search for more papers by this author, OSCAR H. COMESS, M.D.Search for more papers by this author, THOMAS A. NOBLE, M.D.Search for more papers by this author, MARK M. POMARANC, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-48-3-616 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptModern medical science has made such tremendous strides in the field of therapeutics that many older drugs, especially if potentially productive of untoward and dangerous side-effects, have been discredited and have fallen into disuse. Admittedly, many such drugs have marked therapeutic value and are deserving of further investigation and clinical trial before they are completely discarded.Aminopyrine, by force of historical circumstances, has been such a discredited drug for many years.1, 2a, 3c, 4b, 5, 6, 7, 8The danger of agranulocytosis resulting from its use is real and well established, but undoubtedly has been overemphasized.1, 2a, 4b, 5, 6,...Bibliography1. KrackeParker RREP: The relationship of drug therapy to agranulocytosis, J. A. M. A. 105: 960, 1935. CrossrefGoogle Scholar2. GoodmanGilman LA: The pharmacological basis of therapeutics, 1941, The Macmillan Company, New York, (a) p. 250, (b) p. 248-249, (c) p. 226-227, (d) p. 229. Google Scholar3. Sollmann TA: A manual of pharmacology and its application to therapeutics and toxicology, 1941, W. B. Saunders Co., Philadelphia, (a) p. 527, (b) p. 504, (c) p. 526. Google Scholar4. Hyman HT: An integrated practice of medicine, 1946, W. B. Saunders and Co., Philadelphia, (a) Vol. I, p. 195, (b) Vol. II, p. 1,096, (c) Vol. II, p. 1, 184. Google Scholar5. KrackeParker RRFP: Agranulocytosis, J. Lab. and Clin. Med. 19: 799, 1934. Google Scholar6. Phillips E: Aminopyrine in the treatment of rheumatic fever, Permanente Found. M. Bull. 5: 31, 1947. MedlineGoogle Scholar7. Editorial: The danger of amidopyrine, Brit. M. J. 1: 1,292, 1952. Google Scholar8. Hart FD: Current therapeutics. LXVII. Phenylbutazone (Butazolidin), Practitioner 171: 84, 1953. MedlineGoogle Scholar9. Special Report of the Council on Pharmacy and Chemistry: The relation of aminopyrine and barbituric acid derivatives to agranulocytopenia, J. A. M. A. 102: 2,183, 1934. Google Scholar10. Schultz MP: The use of amidopyrine in rheumatic fever, Arch. Int. Med. 48: 1,138, 1931. CrossrefGoogle Scholar11. BrodieAxelrod BBJ: The fate of aminopyrine (Pyramidon) in man and methods for the estimation of aminopyrine and its metabolites in biological material, J. Pharmacol. and Exper. Therap. 99: 171, 1950. MedlineGoogle Scholar12. Dilling WJ: Modern therapeutics. VIII. Sedatives and analgesics, Practitioner 144: 189, 1940. Google Scholar13. Kahn BS: The use of amidopyrine in a case of diabetes insipidus, J. A. M. A. 100: 1,593, 1933. CrossrefGoogle Scholar14. CulliganPendergast JMHJ: Amidopyrine in diabetes insipidus, Minnesota Med. 16: 635, 1933. Google Scholar15. Woolley VJ: Modern therapeutics. XIV. Antipyretics, Practitioner 145: 132, 1940. Google Scholar16. Scherf D: Pyramidon beim Diabetes insipidus, Wien. Arch. f. inn. Med. 22: 457, 1932. Google Scholar17. PfeifferLeeHemmensHasegawa CCREESA: The eosinophil response in normal human subjects after antipyretic analgesic drugs, Proc. Inst. Med. Chicago 18: 96, 1950. Google Scholar18. Hailman HF: ACTH and cortisone vs. salicylates, J. Clin. Endocrinol. and Metabolism 12: 454, 1952. CrossrefGoogle Scholar19. Sturgis CC: Review of some of the more recent advances in the study of blood diseases, Science 81: 367, 1935. CrossrefMedlineGoogle Scholar20. SimonMetz LDMH: Amidopyrine and the circulating leucocytes. Effect of prolonged administration on the number and type of white blood cells, J. Lab. and Clin. Med. 21: 1,154, 1936. Google Scholar21. DavisFrissell JSLF: Amidopyrine sensitivity, J. Lab. and Clin. Med. 23: 107, 1937. Google Scholar22. Editorial: Antihistamines for colds, J. A. M. A. 142: 570, 1950. CrossrefGoogle Scholar23. Herz LF: The role of amidopyrine in the etiology of granulocytopenia with special reference to its chemical structure, J. Lab. and Clin. Med. 20: 33, 1934. Google Scholar24. SteinbrockerBerkowitzEhrlichElkind OSMM: Phenylbutazone therapy of arthritis and other painful musculoskeletal disorders, J. A. M. A. 150: 1,087, 1952. CrossrefGoogle Scholar25. Collier JT: Treatment of measles with amidopyrine, Brit. M. J. 1: 1,093, 1930. CrossrefGoogle Scholar26. BorovskySteigmann MPF: Amidopyrine in the treatment of measles, J. A. M. A. 100: 1,859, 1933. CrossrefGoogle Scholar27. Swift HF: Rheumatic heart disease, pathogenesis and etiology in their relation to therapy and prophylaxis, Medicine 19: 417, 1940. CrossrefGoogle Scholar28. Christian HA: Rheumatic fever, in Osler's Principles and practice of medicine, 15th Ed., 1944, Appleton-Century Co., New York, p. 106. Google Scholar29. HeningerMcHardy BRG: Aminopyrine treatment of rheumatic endocarditis associated with active rheumatic infection, South. M. J. 31: 1,056, 1938. CrossrefGoogle Scholar30. Carter S: Use of anticonvulsive drugs, GP 4: 41 (Nov.) 1951. MedlineGoogle Scholar31. WyngaardenSeever JBMH: The toxic effects of antihistaminic drugs, J. A. M. A. 145: 277, 1951. CrossrefMedlineGoogle Scholar32. KutscherLaneSegall AHSLR: Clinical toxicity of antibiotics and sulfonamides: comparative review of literature based on 104,672 cases treated systemically, J. Allergy 25: 135, 1954. CrossrefMedlineGoogle Scholar33. BeebeProppMcClintockVersaci RTSJCA: Fatal agranulocytosis during treatment of toxic goiter with propylthiouracil, Ann. Int. Med. 34: 1,035, 1951. LinkGoogle Scholar34. Horbaczewski J: Agranulocytosis associated with chlorpromazine therapy, Canad. M. A. J. 75: 412, 1956. MedlineGoogle Scholar35. BenderHoxseyDeMarsh CERJQB: Neutropenia in a patient treated with a mercurial diuretic and its response to BAL, Ann. Int. Med. 33: 1,285, 1950. LinkGoogle Scholar36. RosenbaumRaveno HWS: Agranulocytosis and toxic hepatitis from methimazole, J. A. M. A. 152: 27, 1953. CrossrefMedlineGoogle Scholar37. SilvermanWorthen JJJF: Agranulocytosis in a patient treated with mercurial diuretics, J. A. M. A. 148: 200, 1952. CrossrefMedlineGoogle Scholar38. CrokeBerry ARJW: Agranulocytosis occurring during methimazole ("Tapazole") therapy, J. A. M. A. 148: 45, 1952. CrossrefGoogle Scholar39. ColwellSandoLang ARDESJ: Propylthiouracil-induced agranulocytosis, toxic hepatitis, and death, J. A. M. A. 148: 639, 1952. CrossrefMedlineGoogle Scholar40. HagermanFranzblau DDSA: Gantrisin (Sulfisoxazole)-induced granulocytopenia, J. A. M. A. 147: 1,657, 1951. CrossrefGoogle Scholar41. InouyeMillarTownsend MJJH: Agranulocytosis following maintenance dosage of Pronestyl, J. A. M. A. 147: 652, 1951. CrossrefMedlineGoogle Scholar42. HaunzCardyGraham EAJDCM: Agranulocytosis due to Gantrisin, J. A. M. A. 144: 1,179, 1950. CrossrefGoogle Scholar43. BeckBrowneJohnsonKennedyMcKenzie JCJSLGBJDW: Occurrence of peritonitis during ACTH administration, Canad. M. A. J. 62: 423, 1950. MedlineGoogle Scholar44. HalifHareGlasser DVCCGH: Perforated duodenal ulcer associated with pituitary adrenocorticotropic hormone (ACTH) therapy, J. A. M. A. 144: 996, 1950. CrossrefMedlineGoogle Scholar45. Smyth GA: Activation of peptic ulcer during pituitary adrenocorticotropic hormone therapy, J. A. M. A. 145: 474, 1951. CrossrefMedlineGoogle Scholar46. RaganHowesPlotzMeyerBlunt CELCMKJW: Effect of cortisone on the production of granulation tissue in the rabbit, Proc. Soc. Exper. Biol. and Med. 72: 718, 1949. CrossrefMedlineGoogle Scholar47. SpainMalomertHaber DMNA: Effect of cortisone on granulation tissue in mice, Am. J. Path. 26: 710, 1950. Google Scholar48. BakerWhitaker BLWL: Interference with wound healing by the local action of adrenocortical steroids, Endocrinology 46: 544, 1950. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication February 20, 1957.From the Departments of Medicine, Northwestern University Medical School, Mt. Sinai Hospital and Cook County Hospital.†The terms "aminopyrine" and "amidopyrine" are used interchangeably in the literature, often in the same article, and refer to the same substance. The term "aminopyrine" is used here as probably being the more nearly correct.Requests for reprints should be addressed to Leonard Cardon, M.D., 185 North Wabash Avenue Bldg., Chicago, Illinois. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByLetter to the editor: “Mexican aspirin”—a derogatory termChanges in body temperature after administration of antipyretics, LSD, Δ9-THC and related agents: IIPyrazoione-induced agranulocytosis: an epidemiological evaluationAGRANULOCYTOSIS AND PYRAZOLONEEpidemiological evaluation of rare side-effects of mild analgesics.The Incidence of Dipyrone-Induced Agranulocytosis in Greece during 19752 Non-Steroidal Anti-Inflammatory DrugsThe anabolic influence of aminopyrine 1 March 1958Volume 48, Issue 3Page: 616-634KeywordsAntibioticsClinical trialsColitisCorticosteroid therapyDrug therapyDrugsHospital medicineLymphomaStenosisUlcerative colitis Issue Published: 1 March 1958 PDF DownloadLoading ...